48 pioneering case studies to optimise cell line development, increase productivity and minimise costs
Reasons to attend
- Achieve the ultimate goal; Learn how to improve the quality of your cell lines and reduce your time lines with industry case studies from Biogen Idec, Genentech and Merck Serono
- Gain essential regulatory feedback; ensure compliance and speed up your product approval. Make sure you are first to market!
- GSK, Genentech, Pfizer, Abbott and Novartis describe how they optimise their vector development, screening and clone selection methods – do not miss this unique opportunity.
- Discover how transient gene expression is being optimised by leading companies MedImmune, Novartis, Schering Plough. Plus what will it take to use this technology in clinical trials? – keynote from Florian Wurm
- Understand how siRNAs and miRNAs are being investigated to effectively regulate gene expression and improve cell performance – Dr Patrick Walton and Dr Johannes Grillari present latest data.
- Dedicated session on Cell Banking and Cryopreservation – Boehringer Ingelheim discusses its state-of-the-art strategy for preparing and storing cell banks for large- scale production of biopharmaceuticals
Conference Highlights 2010
50+ speakers over 5 days
50+ speakers over 5 days
Alan Dickson
Professor
University of Manchester, UK
|
Manuel Carrondo
CEO
IBET, Portugal
|
John Masters
Professor of Experimental Pathlogy
University College London, UK
|
Padraig Doolan
Program Leader
NICB, Ireland
|
Florian Wurm
Professor of Biotechnology
EPFL
|
Anne Bondgaard Tolstrup
Director, Antibody Expression
Symphogen
|
Ashraf Amanullah
Associate Director
Genentech, USA
|
Nicola Beltraminelli
Director, Protein Department
Vivalis, France
|
..
Exhibitors
..
..
..
..
Choose from 2,3,4 and 5-day pass
..
..
..
5 May 2010: Join our Evening Workshop on Media Development
Plus don’t miss our Media Development evening seminar, discussion and dinner, new for 2010 – Free if you BOOK on a 5 Day Pass
Media Development Evening Seminar Discussion and Dinner,
Tuesday 2 March 2010
- Dr Petra Meissner, Novartis Biologics,
- Dr Rene Fischer, ETH Zürich,
- Dr Héla Kallel, Institut Pasteur de Tunis,
- Dr Ferruccio Messi, President & CEO, Cell Culture Technologies LLC
Attendees to date
Roche Diagnostics GmbH
Boehringer Ingelheim Pharma GmbH & Co KG
Roche Group Glycart Biotechnology
Biotechnology Research Institute
Miltenyi Biotec GmbH
Schering AG
AVEO Pharmaceuticals Inc
Baxter Innovations GmbH
Institut De Rechercne Pierre Fabre
Bio Technology General
Crucell NV
Glycart Biotechnology AG
Transgene
Institut de Recherche Pierre Fabre
Genentech
Promogene
BioInvent International AB
Sanofi Pasteur
BioGeneriX AG
VIVALIS Instituit Servier
MorphoSys AG
Phadia GmbH
Lek Pharmaceuticals d d
Merck KGaA
National Institute of Health Vaccine Research Centre
Kyowa Hakko Kirin Co Ltd
LFB Biotechnologies
Novartis Institutes for BioMedical Research
Amgen Inc
GlaxoSmithKline
Inno Biologics SDN BHD
MedImmune
Synthon BV
Chromocell Corporation
Genentech Inc
IBI Istituto Biochimico lorencini SpA
Company Name
MacroGenics Inc
Novo Nordisk A/S
Abbott GMBH & Co KG
Neurimmune Therapeutics AG
Laboratorios Almirall SA
Biogen Idec
Ganymed Pharmaceuticals
Merck Serono SA Geneva
Regeneron Pharmaceuticals Inc
Micromet AG
GlaxoSmithKline Biologicals
ITEM
UCB Group
CEVEC Pharmaceuticals GmbH
..
News
..
..
news not found
..
Sponsors
Poll
Will CHO cell lines be the expression system of choice in 5 years time?
Please select an answer
